76
|
Markus M, Streibelt M, Schuler M, Bethge M. Therapiedosis in der medizinisch-beruflich orientierten Rehabilitation in der Orthopädie: eine Analyse erbrachter therapeutischer Leistungen. DAS GESUNDHEITSWESEN 2017. [DOI: 10.1055/s-0037-1605690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
77
|
Heard P, Ackerman J, Coffing S, Dobo K, Schuler M. Fluorescent tubulin polymerization assay to characterize moa of genotoxic compounds — A validation study. J Pharmacol Toxicol Methods 2017. [DOI: 10.1016/j.vascn.2017.02.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
78
|
Guberina M, Eberhardt W, Stuschke M, Gauler T, Heinzelmann F, Cheufou D, Kimmich M, Friedel G, Schmidberger H, Darwiche K, Jendrossek V, Schuler M, Stamatis G, Pöttgen C. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. Ann Oncol 2017; 28:1084-1089. [DOI: 10.1093/annonc/mdx069] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
79
|
Schuler M, Paz-Ares L, Sequist L, Wu YL, Geater S, Märten A, Fan J, Park K, Yang JH. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
80
|
Schuler M, Jelusic D, Wittmann M, Schultz K. Fatigue bei Patienten mit unkontrolliertem Asthma bronchiale vor, zu Beginn und am Ende einer stationären pneumologischen Rehabilitation. Pneumologie 2017. [DOI: 10.1055/s-0037-1598584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
81
|
Leupoldt A, Reijnders T, Petersen S, Stenzel N, Schuler M, Wittmann M, Jelusic D, Schultz K. Disease-specific fears impact outcomes of pulmonary rehabilitation in patients with COPD. Pneumologie 2017. [DOI: 10.1055/s-0037-1598582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
82
|
Schuler M, Jelusic D, Wittmann M, Wagner R, Seidl H, Nowak D, Faller H, Schultz K. Sind bereits vor Beginn einer bewilligten stationären pneumologischen Rehabilitation bei Patienten mit unkontrolloiertem Asthma gesundheitsrelevante Veränderungen eingetreten? Pneumologie 2017. [DOI: 10.1055/s-0037-1598585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
83
|
Mühlig S, Haarig F, Rölz M, Loth F, Eppert M, Zeschke M, Schuler M, Wittmann M, Jelusic D, Schultz K. Zusammenhang von Rauchen und Depressivität bei COPD-Patienten in der pneumologischen Rehabilitation. Pneumologie 2017. [DOI: 10.1055/s-0037-1598577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
84
|
Mühlig S, Haarig F, Rölz M, Loth F, Eppert M, Zeschke M, Schuler M, Wittmann M, Kirchhof R, Schwarz M, Schultz K. Psychische Komorbidität mit Depressionen bei Asthma-Patienten in der pneumologischen Rehabilitation. Pneumologie 2017. [DOI: 10.1055/s-0037-1598583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
85
|
Schenk J, Jelusic D, Wittmann M, Schultz K, Schuler M. Erfassung von Angst bei COPD – Faktorielle Validität und Messinvarianz über die Zeit des Generalized Anxiety Disorder Questionnaire (GAD-7). Pneumologie 2017. [DOI: 10.1055/s-0037-1598581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
86
|
Wingart S, Lehbert N, Jelusic D, Wittmann M, Schuler M, Schultz K. Der 1-Minuten-Sit-to-Stand Test (1-Min.-STST) bei Patienten mit Asthma bronchiale im Rahmen der pneumologischen Rehabilitation: Wie verändert sich der 1-Min.-STST durch die Rehabilitation und in wieweit korreliert dies mit dem 6-Minuten-Gehtest (6MGT)? Pneumologie 2017. [DOI: 10.1055/s-0037-1598471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
87
|
Schuler M, Jelusic D, Wittmann M, Schultz K. Einfluss von Rauchen und Sport auf die Lebensqualität (Dimensionen des St. George Respiratory Questionnaire, SGRQ) während und nach stationärere pneumologischer Rehabilitation. Pneumologie 2017. [DOI: 10.1055/s-0037-1598578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
88
|
Schultz K, Jelusic D, Wittmann M, Wagner R, Seidl H, Nowak D, Faller H, Schuler M. Die nummerische Ratingskala des EQ-5D als Outcomeparameter der Rehabilitation von Patienten mit unkontrolliertem Asthma. Pneumologie 2017. [DOI: 10.1055/s-0037-1598261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
89
|
Wingart S, Lehbert N, Jelusic D, Wittmann M, Schuler M, Schultz K. Der 6-Minuten-Gehtest (6MGT) bei Patienten mit Asthma bronchiale im Rahmen der pneumologischen Rehabilitation (PR): Brauchen wir jeweils zwei Gehtests zu Beginn und am Ende des Reha-Programms? Pneumologie 2017. [DOI: 10.1055/s-0037-1598468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
90
|
Abstract
BACKGROUND Opioids are increasingly used in the elderly. Side effects differ compared to other analgesics. PURPOSE In this review article, special aspects about using opioids for noncancer pain in older people and in geriatric patients are identified. CURRENT SITUATION So far randomized controlled trials for the indication of and comparison between various opioids have been performed in middle-aged patients and not exclusively in geriatric patients or elderly (> 75 years). Furthermore, the evidence for multimorbid elderly patients with respect to side effects is also very poor. RECOMMENDATIONS The indication for opioid therapy should be narrow. The patient and their caregivers must be provided patient information regarding opioid therapy. The principle "start low, go slow" is highly recommended. To reduce the risk of falls, longer acting opioids should be used and short acting opioids should be avoided. Everyday relevant negative effects on cognition are possible in opioid use and have to be observed. As recommended in the recently published German guideline for long-term use of opioids in noncancer pain a critical check after 3 months and in case of dosing over 120 mg morphine equivalents is advisable, especially for older patients. Liver and kidney function and drug interactions have to be taken into consideration like in every age group.
Collapse
|
91
|
Schuler M, Paz-Ares L, Sequist L, Tan E, Mok T, Hirsh V, O’Byrne K, Zhang L, Yamamoto N, Boyer M, Shah R, Bennouna J, Dickgreber N, De Grève J, Love J, Märten A, Fan J, Ehrnrooth E, Park K, Yang J. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30648-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
92
|
Häuser W, Bock F, Engeser P, Hege-Scheuing G, Hüppe M, Lindena G, Maier C, Norda H, Radbruch L, Sabatowski R, Schäfer M, Schiltenwolf M, Schuler M, Sorgatz H, Tölle T, Willweber-Strumpf A, Petzke F. [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain]. Schmerz 2016; 29:109-30. [PMID: 25616996 DOI: 10.1007/s00482-014-1463-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND The regular update of the German S3 guidelines on long-term opioid therapy for chronic noncancer pain (CNCP), the"LONTS" (AWMF registration number 145/003), began in November 2013. METHODS The guidelines were developed by 26 scientific societies and two patient self-help organisations under the coordination of the Deutsche Schmerzgesellschaft (German Pain Society). A systematic literature search in the Cochrane Central Register of Controlled Trials (CENTRAL), Medline and Scopus databases (up until October 2013) was performed. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine. The strength of the recommendations was established by multistep formal procedures, in order to reach a consensus according to German Association of the Medical Scientific Societies ("Arbeitsgemeinschaft der Wissenschaftlich Medizinischen Fachgesellschaften", AWMF) regulations. The guidelines were reviewed by the Drug Commission of the German Medical Association, the Austrian Pain Society and the Swiss Association for the Study of Pain. RESULTS Opioids are one drug-based treatment option for short- (4-12 weeks), intermediate- (13-25 weeks) and long-term (≥ 26 weeks) therapy of chronic osteoarthritis, diabetic polyneuropathy, postherpetic neuralgia and low back pain. Contraindications are primary headaches, as well as functional somatic syndromes and mental disorders with the (cardinal) symptom pain. For all other clinical presentations, a short- and long-term therapy with opioid-containing analgesics should be evaluated on an individual basis. Long-term therapy with opioid-containing analgesics is associated with relevant risks (sexual disorders, increased mortality). CONCLUSION Responsible application of opioid-containing analgesics requires consideration of possible indications and contraindications, as well as regular assessment of efficacy and adverse effects. Neither an uncritical increase in opioid application, nor the global rejection of opioid-containing analgesics is justified in patients with CNCP.
Collapse
|
93
|
Lordick F, Schuler M, Al-Batran SE, Zvirbule Z, Manikhas G, Rusyn A, Vinnyk Y, Vynnychenko I, Fadeeva N, Nechaeva M, Dudov A, Gotovkin E, Pecheniy A, Bazin I, Bondarenko I, Melichar B, Huber C, Sahin U, Türeci Ö. 220O Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw582.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
94
|
Lordick F, Schuler M, Al-Batran SE, Zvirbule Z, Manikhas G, Rusyn A, Vinnyk Y, Vynnychenko I, Fadeeva N, Nechaeva M, Dudov A, Gotovkin E, Pecheniy A, Bazin I, Bondarenko I, Melichar B, Huber C, Sahin U, Tu¨ reci O. 220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00377-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
95
|
Yang JH, Sequist L, Zhou C, Schuler M, Geater S, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Märten A, Massey D, Wind S, Wu YL. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol 2016; 27:2103-2110. [DOI: 10.1093/annonc/mdw322] [Citation(s) in RCA: 132] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 07/29/2016] [Indexed: 11/13/2022] Open
|
96
|
Schuler M, Lukasczik M, Laterveer H, Weilbach F, Presl M, Presl M, Knörzer J, Neuderth S. [Formative Evaluation of the "MBO® Kompakt-Neurowoche" - An Intensified Work-Related Rehabilitation Program for Neurological Patients]. REHABILITATION 2016; 55:312-318. [PMID: 27728938 DOI: 10.1055/s-0042-116582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Objectives: The MBO® Kompakt-Neurowoche is offered as a work-related medical rehabilitation measure (based on allocation by a physician) following a regular neurological rehabilitation program with a duration of 7 days. Program access, process, and outcomes were examined in terms of a formative evaluation. Method: Pre-post-questionnaire data from 5 data points were used: start of regular rehabilitation (T0); start of work-related rehabilitation (T1); end of work-related rehabilitation (T2); 6-months follow-up (T3); 12-months follow-up (T4). Results: N=252 patients (75% male, 48±10 years) were included. Participants report a higher work-related treatment motivation and a more positive subjective return-to-work prognosis as compared to nonparticipants (N=215). At T4, 76% are (very) satisfied with the program. Patients rate therapy elements focusing on the assessment and improvement of work-related capacity and memory as especially useful. Assistance in developing job-related alternatives should be optimized. Conclusions: Patients participating in the work-related program report both vocational problems and a high motivation to deal with these problems during rehabilitation. The program is rated as useful with regard to return to work and the management of workplace issues.
Collapse
|
97
|
Schuler M, Al-Batran SE, Zvirbule Z, Manikhas G, Lordick F, Rusyn A, Vinnyk Y, Vynnychenko I, Fadeeva N, Nechaeva M, Dudov A, Gotovkin E, Pecheniy A, Bazin I, Bondarenko I, Melichar B, Huber C, Türeci Ö, Sahin U. Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.06] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
98
|
Cappuzzo F, Soo R, Hochmair M, Schuler M, Mok T, Stehle G, Cseh A, Lorence R, Linden S, Forman N, Tsai CM. Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
99
|
Kasper S, Meiler J, Knipp H, Höhler T, Reimer P, Steinmetz H, Berger W, Linden G, Ting S, Markus P, Paul A, Dechêne A, Schumacher B, Kostbade K, Worm K, Schmid K, Herold T, Schuler M, Trarbach T. Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.56] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
100
|
Joerger M, Soo R, Cho B, Mendivil AN, Sayehli C, Richly H, Tai D, Kim DW, Wolf J, Cassier P, Ellinghaus P, Hildebrandt S, Behre S, Helmbrecht C, Kerpen S, Zielinski D, Ince S, Rajagopalan P, Ocker M, Schuler M. developmental therapeutics Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.10] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|